Pipeline
Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.
Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.
Clinical Projects
- Program/ Target Name
- Indication
- Discovery
- Preclinical
- Phase I
- Phase II
- Partner
- Anticipated
Milestones
- RVU120
CDK8/19 -
- AML/MDS
-
-
-
-
-
Additional Phase I
data in Q2 2023
- SOLID TUMORS
-
-
-
-
-
Additional Phase I
data in Q2 2023
- SEL24 (MEN1703)
PIM/FLT3 -
- AML
-
-
-
-
-
In vivo POC
in 2023
Discovery & Preclinical Projects
- Program/ Target Name
- Indication
- Discovery
- Preclinical
- Phase I
- Phase II
- Partner
- Anticipated
Milestones
Synthetic Lethality
- PRMT5
-
- Solid tumors
-
-
-
-
-
Development candidate
in 2023
- WRN
-
- Solid tumors
-
-
-
-
-
- NOVEL TARGETS
-
- ONCOLOGY
-
-
-
-
-
Immuno-oncology
- STING Standalone
-
- Solid tumors
-
-
-
-
-
- STING ADC
-
- ONCOLOGY
-
-
-
-
-
- HPK1
-
- Solid tumors
-
-
-
-
-
- Immune Modulation Research Collaboration (Multi-Target)
-
-
- Discovery Collaboration
-
-